Andrew Morgenthaler

Andrew Morgenthaler is a Scientist II at Amyris, a biotechnology company based in Emeryville, California.1 He is a molecular biologist with a diverse background in various scientific disciplines and industry experience.

Education and Career Path

Andrew holds a Ph.D. in Molecular, Cellular, and Developmental Biology from the University of Colorado Boulder, which he completed in 2020.12 Prior to his doctoral studies, he earned a B.S. in Biochemistry from Tufts University, graduating cum laude in 2011.1

His career trajectory includes:

• Scientist II at Amyris (October 2022 - Present)
• Scientist II at Zymergen (July 2021 - October 2022)
• Scientist I at Zymergen (July 2020 - June 2021)
• Associate Scientist at Amyris Inc. (November 2011 - June 2014)

Expertise and Contributions

Andrew is described as a self-motivated, creative, collaborative, and energetic molecular biologist.1 His areas of expertise include:

• Metabolic engineering
• Materials chemistry
• Laboratory evolution
• Enzymology
• Analytical chemistry
• Bioinformatics

During his time at Zymergen, Andrew worked on identifying bio-reachable molecules with superior material properties, resulting in over 10 early-stage research projects.1 He has also been involved in designing, building, testing, and analyzing high-throughput strain libraries for the production of these molecules.

Research and Publications

Andrew has contributed to several high-impact publications and presentations at conferences.1 His work has led to a ~$1.5 million NIH grant, demonstrating the significance of his research in the field. He has also collaborated with local biotech companies on projects involving multiplexed mutagenesis libraries, providing insights into the synonymous mutation fitness landscape of E. coli.

Andrew's research profile can be found on Google Scholar, where his publications and citations are listed.3

Current Role at Amyris

As a Scientist II at Amyris, Andrew likely continues to apply his expertise in molecular biology and synthetic biology to develop sustainable bio-based products.4 His experience in enzyme discovery, genetic engineering, and high-throughput data analysis makes him a valuable asset to Amyris's scientific research and development team.